High failure rates in treatment of streptococcal periprosthetic joint infection

Bone and Joint Journal

Volumn 99B, Issue 5, 2017, Pages 653-659

  Akgun D ^a   Trampuz, A ^a   Perka, C ^a   Renz, N ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; LEVOFLOXACIN; PENICILLIN DERIVATIVE; RIFAMPICIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEBRIDEMENT; FEMALE; FOLLOW UP; HIP ARTHROPLASTY; HUMAN; MALE; NONHUMAN; OUTCOME ASSESSMENT; PERIPROSTHETIC JOINT INFECTION; PRIORITY JOURNAL; PROSTHESIS FIXATION; REVISION ARTHROPLASTY; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS DYSGALACTIAE; STREPTOCOCCUS GALLOLYTICUS; STREPTOCOCCUS GORDONII; STREPTOCOCCUS INFECTION; STREPTOCOCCUS MITIS; STREPTOCOCCUS ORALIS; STREPTOCOCCUS PARASANGUINIS; STREPTOCOCCUS THERMOPHILUS; SURVIVAL TIME; TOTAL KNEE ARTHROPLASTY; TREATMENT FAILURE; TWO-STAGE REVISION; ADVERSE EFFECTS; CLASSIFICATION; HIP PROSTHESIS; HIP REPLACEMENT; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; KNEE PROSTHESIS; KNEE REPLACEMENT; MICROBIOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; POSTOPERATIVE PERIOD; PROCEDURES; PROSTHESIS-RELATED INFECTIONS; REOPERATION; RETROSPECTIVE STUDY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; COMBINED MODALITY THERAPY; DEBRIDEMENT; FEMALE; HIP PROSTHESIS; HUMANS; KAPLAN-MEIER ESTIMATE; KNEE PROSTHESIS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PROSTHESIS-RELATED INFECTIONS; REOPERATION; RETROSPECTIVE STUDIES; RIFAMPIN; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; TREATMENT FAILURE;

EID: 85019352883     PISSN: 20494394     EISSN: 20494408     Source Type: Journal    
DOI: 10.1302/0301-620X.99B5.BJJ-2016-0851.R1     Document Type: Article

References (29)

1. Zeller V, Lavigne M, Biau D, et al. Outcome of group B streptococcal prosthetic hip infections compared to that of other bacterial infections. Joint Bone Spine 2009; 76: 491-496.
2. Zeller V, Lavigne M, Leclerc P, et al. Group B streptococcal prosthetic joint infections: a retrospective study of 30 cases. Presse Med 2009; 38: 1577-1584.
3. Schwartz B, Schuchat A, Oxtoby MJ, et al. Invasive group B streptococcal disease in adults. A population-based study in metropolitan Atlanta. JAMA 1991; 266: 1112-1114.
4. Jenkins PJ, Clement ND, Gaston P, et al. Invasive group B streptococcal disease in an orthopaedic unit. J Hosp Infect 2010; 76: 231-233.
5. Corvec S, Illiaquer M, Touchais S, et al. Clinical features of group B Streptococcus prosthetic joint infections and molecular characterization of isolates. J Clin Microbiol 2011; 49: 380-382.
6. Duggan JM, Georgiadis G, VanGorp C, Kleshinski J. Group B streptococcal prosthetic joint infections. J South Orthop Assoc 2001; 10: 209-214.
7. Sendi P, Christensson B, Uçkay I, et al. Group B streptococcus in prosthetic hip and knee joint-associated infections. J Hosp Infect 2011; 79: 64-69.
8. Meehan AM, Osmon DR, Duffy MC, Hanssen AD, Keating MR. Outcome of penicillin-susceptible streptococcal prosthetic joint infection treated with debridement and retention of the prosthesis. Clin Infect Dis 2003; 36: 845-849.
9. Betz M, Abrassart S, Vaudaux P, et al. Increased risk of joint failure in hip pros-theses infected with Staphylococcus aureus treated with debridement, antibiotics and implant retention compared to Streptococcus. Int Orthop 2015; 39: 397-401.
10. Everts RJ, Chambers ST, Murdoch DR, Rothwell AG, McKie J. Successful antimicrobial therapy and implant retention for streptococcal infection of prosthetic joints. ANZ J Surg 2004; 74: 210-214.
11. Fiaux E, Titecat M, Robineau O, et al. Outcome of patients with streptococcal prosthetic joint infections with special reference to rifampicin combinations. BMC Infect Dis 2016; 16: 568.
12. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351: 1645-1654.
13. Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2013; 56: 1-25.
14. Krenn V, Morawietz L, Perino G, et al. Revised histopathological consensus classification of joint implant related pathology. Pathol Res Pract 2014; 210: 779-786.
15. Trampuz A, Piper KE, Jacobson MJ, et al. Sonication of removed hip and knee prostheses for diagnosis of infection. N Engl J Med 2007; 357: 654-663.
16. Diaz-Ledezma C, Higuera CA, Parvizi J. Success after treatment of periprosthetic joint infection: a Delphi-based international multidisciplinary consensus. Clin Orthop Relat Res 2013; 471: 2374-2382.
17. Zürcher-Pfund L, Uçkay I, Legout L, et al. Pathogen-driven decision for implant retention in the management of infected total knee prostheses. Int Orthop 2013; 37: 1471-1475.
18. Zimmerli W, Moser C. Pathogenesis and treatment concepts of orthopaedic biofilm infections. FEMS Immunol Med Microbiol 2012; 65: 158-168.
19. Sendi P, Banderet F, Graber P, Zimmerli W. Clinical comparison between exogenous and haematogenous periprosthetic joint infections caused by Staphylococcus aureus. Clin Microbiol Infect 2011; 17: 1098-1100.
20. Peersman G, Laskin R, Davis J, Peterson M. Infection in total knee replacement: a retrospective review of 6489 total knee replacements. Clin Orthop Relat Res 2001; 392: 15-23.
21. Dunne WM Jr, Mason EO Jr, Kaplan SL. Diffusion of rifampin and vancomycin through a Staphylococcus epidermidis biofilm. Antimicrob Agents Chemother 1993; 37: 2522-2526.
22. Zheng Z, Stewart PS. Penetration of rifampin through Staphylococcus epidermidis biofilms. Antimicrob Agents Chemother 2002; 46: 900-903.
23. Singh R, Ray P, Das A, Sharma M. Penetration of antibiotics through Staphylococcusaureus and Staphylococcus epidermidis biofilms. J Antimicrob Chemother 2010; 65: 1955-1958.
24. El Helou OC, Berbari EF, Lahr BD, et al. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis 2010; 29: 961-967.
25. Chargui M, Suvà D, Christofilopoulos P, et al. Deep soft tissue infections. Rev Med Suisse 2014; 10: 920-924. (In French)
26. Kaur H, Kumar P, Ray P, Kaur J, Chakraborti A. Biofilm formation in clinical isolates of group B streptococci from north India. Microb Pathog 2009; 46: 321-327.
27. Borges S, Silva J, Teixeira P. Survival and biofilm formation by Group B streptococci in simulated vaginal fluid at different pHs. Antonie Van Leeuwenhoek 2012; 101: 677-682.
28. Yang L, Liu Y, Wu H, et al. Combating biofilms. FEMS Immunol Med Microbiol 2012; 65: 146-157.
29. Ho YR, Li CM, Yu CH, et al. The enhancement of biofilm formation in Group B strep-tococcal isolates at vaginal pH. Med Microbiol Immunol 2013; 202: 105-115.